A Trial for Prevention of Loss of the Effect of Biological Drugs in Patients With Inflammatory Bowel Disease

NCT03843697 | Unknown

• 1 other identifier: OS-002
• Study Type: interventional
• Target: 20
• Locations: 0 countries
• Sites: N/A

Brief Summary

Trial for IBD patients non-responsive to biological drugs, using medical app reminding patients to take their physician-prescribed medications

Conditions

Inflammatory Bowel Diseases

Outcome Measures

Primary Outcomes (1)

• Proportion of subjects with reduction chron's disease activity index score more than 100 points during the study;

  Proportion of subjects with reduction chron's disease activity index score more than 100 points during the study;

  10 weeks

Secondary Outcomes (1)

• Proportion of subjects achieving clinical remission or response without steroid rescue therapy during the study;

  10 weeks

Study Arms (1)

Patients with IBD who develop resistance to anti TNF

EXPERIMENTAL

Patients with inflammatory bowel disease who developed partial or complete resistance to anti TNF based drugs

Device: An App for reminding patients to take their medication

Interventions

An App for reminding patients to take their medication DEVICE

Open-label, single-center study, up to 20 adults (\>18) male and female with inflammatory bowel disease (chorn's disease, ulcerative colitis), unresponsive to biological drugs, will participate in a 4-week observation period during which no change in drugs is permitted. The patients will then begin 10-week treatment by taking their medications according to a semi-random schedule that is pre-set for them by the physician using the same drugs the patient is taking and only changing the dose and times of taking them each day while keeping the drugs within their therapeutic window.

Also known as: Oberon APP

Patients with IBD who develop resistance to anti TNF

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients on a stable dose within the last 6 weeks of any type of anti TNF agent or any other biological agent
• ASA (mesalamine), and immunomodulatory, or immunosuppressive agent, and symptomatic relief (anti-diarrheals) for patients are allowed in a stable dose (6 weeks).
• Non-smoking (by declaration) for a period of at least 6 months.
• Females of childbearing potential must be non-pregnant (as determined by a serum pregnancy test at screening and again, prior to each dosing session) and agree to use adequate contraceptive means throughout the study.
• No known history of significant neurological, renal, cardiovascular, respiratory (asthma), endocrinological, gastrointestinal, primary hematopoietic disease, neoplasm, or any other clinically significant medical disorder other than Crohn's disease and its complications, which in the investigator's judgment contraindicate administration of the study medications.
• No history of drug or alcohol abuse.
• Screening tests must meet the following criteria: HGB ≥8.5 g/dL, platelets ≥ 100,000/ mm³, WBC: 3500-12,000/mm³, serum albumin above 2.5 g/dL, amylase, lipase and total bilirubin within normal limits. ALT, AST, alkaline phosphatase up to 1.5 times normal limits.
• No clinically significant abnormalities in screening physical exam.
• Negative HIV, Hepatitis B and Hepatitis C serology tests within 2 years.
• Patients must be able to adhere to the visit schedule and protocol requirements and be available to complete the study.
• Patients must satisfy a medical examiner about their fitness to participate in the study.
• Patients must provide written informed consent to participate in the study.

You may not qualify if:

• Patients with evidence of other serious infectious, autoimmune, hepatic, nephritic or systemic disease or compromised organ function.
• Patients with a present colostomy, ileostomy or subtotal colectomy with ileorectal anastomosis.
• Symptomatic stenosis or ileal strictures, x-ray evidence of fibrosed bowel.
• Patients presenting with, or with a history of persistent intestinal obstruction, bowel perforation, uncontrolled GI bleed or abdominal abscess or infection, toxic megacolon.
• Patients with fistulating CD.
• Short bowel syndrome.
• Patients with a history of GI tract malignancy or IBD-associated malignant changes in the intestines.
• Patients with any clinically significant abnormality upon physical examination or in the clinical laboratory test values.
• A change in the dose of the immunomodulatory or immunosuppressive drug within 6 weeks.
• Over-the-counter drugs, including herbal medications, and prescription drugs (other than those listed above) are not allowed for 7 days prior to first study dosing and throughout the duration of the study
• Receipt of packed RBC's within 3 months prior to the first study dosing and throughout the study.
• Participation in another clinical trial within 30 days prior to first drug administration.
• Patients with an inability to communicate well with the PI and staff (i.e., language problem, poor mental development or impaired cerebral function).
• Patients with any acute medical situation (e.g. acute infection) within 48 hours of first dosing session, which is considered of significance by the Principal Investigator.
• Patients who will be unavailable for the duration of the trial, are likely to be noncompliant with the protocol, or who are felt to be unsuitable by the PI for any other reason.

Sponsors & Collaborators

• Tahel Ilan Ber: lead

Related Publications (1)

• Azmanov H, Ross EL, Ilan Y. Establishment of an Individualized Chronotherapy, Autonomic Nervous System, and Variability-Based Dynamic Platform for Overcoming the Loss of Response to Analgesics. Pain Physician. 2021 May;24(3):243-252.

  PMID: 33988944 DERIVED

MeSH Terms

Conditions

Inflammatory Bowel Diseases

Condition Hierarchy (Ancestors)

Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Intestinal Diseases

Central Study Contacts

Tahel Ilan Ber, MD

CONTACT

972 53 803463; taheli@oberonsci.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DEVICE FEASIBILITY
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Chief Medical Officer

Model Details: The study will assess the effect of adding an app which reminds to take an approved therapy in patients who are already on the drug without a change of the physician's predetermined regimen

Study Record Dates

• First Submitted: December 21, 2018
• First Posted: February 18, 2019
• Study Start: March 1, 2019
• Primary Completion: January 1, 2020
• Study Completion: January 1, 2020
• Last Updated: February 18, 2019

Record last verified: 2019-02

Data Sharing

• IPD Sharing: Will not share